Bioasis Technologies Inc.

As of November 30, 2022, Bioasis Technologies Inc. has 79.41M shares outstanding.

These figures are as of November 30, 2022. The price-to-sales ratio is 48.24, and the price-to-book ratio stands at -5.01.

These figures are as of November 30, 2022. The EV/Sales ratio of 57.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of November 30, 2022, Bioasis Technologies Inc. maintains a current ratio of 0.11, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -82.07, indicating conservative leverage, while an interest coverage ratio of -4.33 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended November 30, 2022. Return on assets (ROA) is negative at -120.62, reflecting losses generated across the asset base.

As of the close on March 6, 2024, Bioasis Technologies Inc.'s stock has declined approximately 75.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended November 30, 2022, Bioasis Technologies Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,141.16 and net profit margin of -1,067.59 provide insight into operational efficiency.

These figures cover the twelve months ended November 30, 2022. Free cash flow yield is negative at -14.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.10, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bioasis Technologies Inc. shareholders.

As of November 30, 2022, Bioasis Technologies Inc. has an Altman Z-Score of -190.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.